Mechanism of anti-tumor effect of dihydroartemisinin

Abstract

Peng Wenmiao, Fu Hongxing, Yu Lifang, Rao Zhiguo. Mechanism of anti-tumor effect of dihydroartemisinin[J]. Journal of International Oncology, 2017, 44(6): 448-.

［1］ Noori S, Hassan ZM, Farsam V. Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line［J］. Chin J Integr Med, 2014, 20(8): 618-623. DOI: 10.1007/s1165501314542. ［2］ Zhang CZ, Pan Y, Cao Y, et al. Histone deacetylase inhibitors facilitate dihydroartemisinininduced apoptosis in liver cancer in vitro and in vivo［J］. PLoS One, 2012, 7(6): e39870. DOI: 10.1371/journal.pone.0039870. ［3］ Zhang ZS, Wang J, Shen YB, et al. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy［J］. Oncol Lett, 2015, 10(1): 379-383. DOI: 10.3892/ol.2015.3183. ［4］ Xu G, Zou WQ, Du SJ, et al. Mechanism of dihydroartemisinininduced apoptosis in prostate cancer PC3 cells: an iTRAQbased proteomic analysis［J］. Life Sci, 2016, 157: 1-11. DOI: 10.1016/j.lfs.2016.05.033. ［5］ Wang Q, Wu S, Zhao X, et al. Mechanisms of dihydroartemisinin and dihydroartemisinin/holotransferrin cytotoxicity in Tcell lymphoma cells［J］. PLoS One, 2015, 10(10): e0137331. DOI: 10.1371/journal.pone.0137331. ［6］ Lu JJ, Chen SM, Zhang XW, et al. The anticancer activity of dihydroartemisinin is associated with induction of irondependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells［J］. Invest New Drugs, 2011, 29(6): 1276-1283. DOI: 10.1007/s1063701094818. ［7］ Ba Q, Zhou N, Duan J, et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor1［J］. PLoS One, 2012, 7(8): e42703. DOI: 10.1371/journal.pone.0042703. ［8］ Ontikatze T, Rudner J, Handrick R, et al. Dihydroartemisinin is a hypoxiaactive anticancer drug in colorectal carcinoma cells［J］. Front Oncol, 2014, 4: 116. DOI: 10.3389/fonc.2014.00116. ［9］ D′Alessandro S, Basilico N, Corbett Y, et al. Hypoxia modulates the effect of dihydroartemisinin on endothelial cells［J］. Biochem Pharmacol, 2011, 82(5): 476-484. DOI: 10.1016/j.bcp.2011.06.002. ［10］ Tai X, Cai XB, Zhang Z, et al. In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism［J］. Oncol Lett, 2016, 12(5): 3701-3706. DOI: 10.3892/ol.2016.5187. ［11］ Zhao X, Zhong H, Wang R, et al. Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxamediated pathway requiring iron and endoperoxide moiety［J］. Oncotarget, 2015, 6(8): 5582-5596. DOI: 10.18632/oncotarget.3336. ［12］ Lu M, Sun L, Zhou J, et al. Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondriadependent pathway［J］. Tumour Biol, 2014, 35(6): 5307-5314. DOI: 10.1007/s1327701416919. ［13］ Guo L, Dong F, Hou Y, et al. Dihydroartemisinin inhibits vascular endothelial growth factorinduced endothelial cell migration by a p38 mitogenactivated protein kinaseindependent pathway［J］. Exp Ther Med, 2014, 8(6): 1707-1712. DOI: 10.3892/etm.2014.1997. ［14］盛庆寿, 王武, 郭洪武. 双氢青蒿素对原发性肝癌大鼠的治疗作用及机制［J］. 中国实验方剂学杂志, 2014, 20(14): 150-154. DOI: 10.13422/j.cnki.syfjx.2014140150. ［15］ Liu J, Wen X, Liu B, et al. Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP2 and MMP9［J］. Mol Med Rep, 2016, 13(3): 2401-2408. DOI: 10.3892/mmr.2016.4872. ［16］ Zhang S, Ma Y, Jiang J, et al. Inhibition of urokinasetype plasminogen activator expression by dihydroartemisinin in breast cancer cells［J］. Oncol Lett, 2014, 7(5): 1375-1380. DOI: 10.3892/ol.2014.1918. ［17］ Wu B, Hu K, Li S, et al. Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer［J］. Oncol Rep, 2012, 27(1): 101-108. DOI: 10.3892/or.2011.1505. ［18］ Sun N, Zhang Q, Xu C, et al. Molecular regulation of ovarian cancer cell invasion［J］. Tumour Biol, 2014, 35(11): 11359-11366. DOI: 10.1007/s1327701424347. ［19］ Hooft van Huijsduijnen R, Guy RK, Chibale K, et al. Anticancer properties of distinct antimalarial drug classes［J］. PLoS One, 2013, 8(12): e82962. DOI: 10.1371/journal.pone.0082962. ［20］ Lucibello M, Adanti S, Antelmi E, et al. PhosphoTCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells［J］. Oncotarget, 2015, 6(7): 5275-5291. DOI: 10.18632/oncotarget.2971. ［21］ Feng X, Li L, Jiang H, et al. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatinresistant ovarian cancer cells: involvement of apoptosis and autophagy［J］. Biochem Biophys Res Commun, 2014, 444(3): 376-381. DOI: 10.1016/j.bbrc.2014.01.053. ［22］ Zhao C, Gao W, Chen T. Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine［J］. Apoptosis, 2014, 19(4): 668-681. DOI: 10.1007/s1049501309530. ［23］ Chen T, Chen M, Chen J. Ionizing radiation potentiates dihydroartemisinininduced apoptosis of A549 cells via a caspase8dependent pathway［J］. PLoS One, 2013, 8(3): e59827. DOI: 10.1371/journal.pone.0059827. ［24］ Jacob JA, Salmani JM, Jiang Z, et al. Autophagy: an overview and its roles in cancer and obesity［J］. Clin Chim Acta, 2017, 468: 85-89. DOI: 10.1016/j.cca.2017.01.028. ［25］ Yu X, Luo A, Liu Y, et al. MiR214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy［J］. Mol Cancer, 2015, 14: 208. DOI: 10.1186/s1294301504804. ［26］ Wang Z, Hu W, Zhang JL, et al. Dihydroartemisinin induces autophagy and inhibits the growth of ironloaded human myeloid leukemia K562 cells via ROS toxicity［J］. FEBS Open Bio, 2012, 2: 103-112. DOI: 10.1016/j.fob.2012.05.002. ［27］ Hu W, Chen SS, Zhang JL, et al. Dihydroartemisinin induces autophagy by suppressing NFκB activation［J］. Cancer Lett, 2014, 343(2): 239-248. DOI: 10.1016/j.canlet.2013.09.035. ［28］ Chen SS, Hu W, Wang Z, et al. p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy［J］. Cancer Biol Ther, 2015, 16(5): 770-779. DOI: 10.1080/15384047.2015.1026477. ［29］李剑. 内质网应激在双氢青蒿素诱导前列腺癌PC3细胞凋亡中的作用研究［D］. 重庆: 重庆医科大学, 2011. ［30］ Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro, and in vivo［J］. Cell Immunol, 2011, 271(1): 67-72. DOI: 10.1016/j.cellimm.2011.06.008. ［31］ Sun Q, Teong B, Chen IF, et al. Enhanced apoptotic effects of dihydroartemisininaggregated gelatin and hyaluronan nanoparticles on human lung cancer cells［J］. J Biomed Mater Res B Appl Biomater, 2014, 102(3): 455-462. DOI: 10.1002/jbm.b.33023.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Mechanism of anti-tumor effect of dihydroartemisinin

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments